Literature DB >> 24085322

Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction.

Chao Huang1, Qian Ba, Qingxi Yue, Junyang Li, Jingquan Li, Ruiai Chu, Hui Wang.   

Abstract

Artemisinin and related compounds (artemisinins), as a frontline treatment for malaria, have been used to save millions of lives. Their potential application in cancer treatment is promising. Nevertheless, the precise mechanisms of action of artemisinins are still controversial. In particular, the system-level influence of artemisinins on protein interactions and regulatory networks remains unknown, limiting progress in development of this class of compounds as anticancer drugs. In the present study, we investigated the mechanism of action of artemisinins in cancer therapy through an analysis based on biological networks. According to experimental evidence from more than 400 literature studies, 558 key proteins were derived and the artemisinins-rewired protein interaction network was constructed. Topological properties were analyzed to show that the protein network was a scale-free biological system. And the modularity analysis and pathway identification were performed. Five key pathways including PI3K-Akt, T cell receptor, Toll-like receptor, TGF-beta and insulin signaling pathways were involved in artemisinins-mediated anticancer effects; their identification was confirmed by microarray data. Based on these results, predictions were made about the targets of artemisinins in various pathways. These results provide a deeper understanding of the molecular mechanisms of action of artemisinins and will contribute to the development and application of this class of compounds in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24085322     DOI: 10.1039/c3mb70342h

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  7 in total

1.  The natural sesquiterpene lactones arglabin, grosheimin, agracin, parthenolide, and estafiatin inhibit T cell receptor (TCR) activation.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Pete T Mitchell; Аnarkul S Kishkentaeva; Zhanar R Shaimerdenova; Gayane A Atazhanova; Sergazy M Adekenov; Mark T Quinn
Journal:  Phytochemistry       Date:  2017-12-22       Impact factor: 4.072

2.  A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.

Authors:  Hanafy M Ismail; Victoria E Barton; Matthew Panchana; Sitthivut Charoensutthivarakul; Giancarlo A Biagini; Stephen A Ward; Paul M O'Neill
Journal:  Angew Chem Int Ed Engl       Date:  2016-04-18       Impact factor: 15.336

3.  A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.

Authors:  Hanafy M Ismail; Victoria E Barton; Matthew Panchana; Sitthivut Charoensutthivarakul; Giancarlo A Biagini; Stephen A Ward; Paul M O'Neill
Journal:  Angew Chem Weinheim Bergstr Ger       Date:  2016-04-18

4.  Predicting cancer-relevant proteins using an improved molecular similarity ensemble approach.

Authors:  Bin Zhou; Qi Sun; De-Xin Kong
Journal:  Oncotarget       Date:  2016-05-31

5.  Artemisinin Prevents Glutamate-Induced Neuronal Cell Death Via Akt Pathway Activation.

Authors:  Shao-Peng Lin; Wenjun Li; Ali Winters; Ran Liu; Shao-Hua Yang
Journal:  Front Cell Neurosci       Date:  2018-04-20       Impact factor: 5.505

6.  K-shell Analysis Reveals Distinct Functional Parts in an Electron Transfer Network and Its Implications for Extracellular Electron Transfer.

Authors:  Dewu Ding; Ling Li; Chuanjun Shu; Xiao Sun
Journal:  Front Microbiol       Date:  2016-04-20       Impact factor: 5.640

7.  Artesunate shows potent anti-tumor activity in B-cell lymphoma.

Authors:  Thea Kristin Våtsveen; Marit Renée Myhre; Chloé Beate Steen; Sébastien Wälchli; Ole Christian Lingjærde; Baoyan Bai; Pierre Dillard; Theodossis A Theodossiou; Toril Holien; Anders Sundan; Else Marit Inderberg; Erlend B Smeland; June Helen Myklebust; Morten P Oksvold
Journal:  J Hematol Oncol       Date:  2018-02-20       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.